Federated Hermes’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.72M Buy
19,667
+1,126
+6% +$197K 0.01% 855
2025
Q4
$3.15M Sell
18,541
-378
-2% -$58K 0.01% 868
2025
Q3
$2.49M Buy
18,919
+2,517
+15% +$302K ﹤0.01% 885
2025
Q2
$1.74M Buy
16,402
+1,078
+7% +$117K ﹤0.01% 979
2025
Q1
$1.9M Sell
15,324
-15,703
-51% -$2.05M ﹤0.01% 944
2024
Q4
$3.82M Sell
31,027
-587
-2% -$69.2K 0.01% 778
2024
Q3
$3.52M Sell
31,614
-81,403
-72% -$8.92M 0.01% 803
2024
Q2
$12.1M Sell
113,017
-15,188
-12% -$1.67M 0.03% 512
2024
Q1
$15.4M Buy
128,205
+8,732
+7% +$1.07M 0.04% 463
2023
Q4
$14.7M Sell
119,473
-4,162
-3% -$519K 0.04% 460
2023
Q3
$16M Buy
123,635
+113,380
+1,106% +$15.1M 0.04% 418
2023
Q2
$1.27M Buy
10,255
+7
+0.1% +$942 ﹤0.01% 1082
2023
Q1
$1.5M Sell
10,248
-70
-0.7% -$10.4K ﹤0.01% 1051
2022
Q4
$1.64M Buy
10,318
+413
+4% +$60.5K ﹤0.01% 973
2022
Q3
$1.32M Sell
9,905
-729
-7% -$111K ﹤0.01% 1030
2022
Q2
$1.66M Sell
10,634
-340
-3% -$52.3K ﹤0.01% 982
2022
Q1
$1.71M Sell
10,974
-2,118
-16% -$307K ﹤0.01% 1084
2021
Q4
$1.67M Sell
13,092
-487
-4% -$64K ﹤0.01% 1104
2021
Q3
$1.77M Sell
13,579
-89,907
-87% -$13.6M ﹤0.01% 1079
2021
Q2
$18.4M Sell
103,486
-4,101
-4% -$710K 0.03% 504
2021
Q1
$17.7M Sell
107,587
-6,904
-6% -$1.14M 0.03% 526
2020
Q4
$18.9M Buy
114,491
+1,207
+1% +$180K 0.04% 484
2020
Q3
$16.2M Sell
113,284
-8,264
-7% -$1.02M 0.04% 457
2020
Q2
$13.4M Buy
121,548
+6,057
+5% +$670K 0.03% 476
2020
Q1
$11.5M Buy
115,491
+7,030
+6% +$909K 0.03% 442
2019
Q4
$16.2M Sell
108,461
-10,892
-9% -$1.48M 0.04% 473
2019
Q3
$15.3M Sell
119,353
-8,024
-6% -$1.08M 0.04% 432
2019
Q2
$18.2M Buy
127,377
+50,895
+67% +$6.84M 0.04% 377
2019
Q1
$10.9M Buy
76,482
+65,091
+571% +$8.49M 0.03% 533
2018
Q4
$1.41M Sell
11,391
-21,235
-65% -$3.15M ﹤0.01% 1161
2018
Q3
$5.49M Buy
32,626
+21,426
+191% +$3.68M 0.01% 779
2018
Q2
$1.93M Sell
11,200
-1,400
-11% -$229K 0.01% 1034
2018
Q1
$1.9M Buy
+12,600
New +$1.85M 0.01% 981
2017
Q4
Sell
-19,200
Closed -$2.81M 2204
2017
Q3
$2.81M Buy
19,200
+3,000
+19% +$454K 0.01% 775
2017
Q2
$2.52M Buy
16,200
+4,200
+35% +$642K 0.01% 811
2017
Q1
$1.74M Buy
12,000
+2,000
+20% +$260K 0.01% 962
2016
Q4
$1.09M Sell
10,000
-6,000
-38% -$668K ﹤0.01% 1109
2016
Q3
$1.94M Hold
16,000
0.01% 855
2016
Q2
$2.26M Buy
16,000
+3,882
+32% +$572K 0.01% 793
2016
Q1
$1.58M Sell
12,118
-1,653
-12% -$206K ﹤0.01% 926
2015
Q4
$1.94M Buy
13,771
+3,758
+38% +$521K 0.01% 885
2015
Q3
$1.33M Buy
10,013
+3
+0% +$517 ﹤0.01% 1016
2015
Q2
$1.76M Buy
10,010
+10
+0.1% +$1.8K 0.01% 971
2015
Q1
$1.73M Hold
10,000
0.01% 1013
2014
Q4
$1.64M Sell
10,000
-6,000
-38% -$996K 0.01% 1030
2014
Q3
$2.57M Buy
16,000
+7,000
+78% +$1.08M 0.01% 868
2014
Q2
$1.32M Sell
9,000
-45,187
-83% -$6.27M ﹤0.01% 1102
2014
Q1
$7.51M Buy
54,187
+1,168
+2% +$176K 0.03% 543
2013
Q4
$6.71M Buy
53,019
+2,577
+5% +$267K 0.02% 552
2013
Q3
$4.64M Buy
+50,442
New +$4.07M 0.02% 608

Other funds holding JAZZ

Federated Hermes's JAZZ Position: Q1 2026 in Review

Federated Hermes increased its Jazz Pharmaceuticals (JAZZ) stake by 6.1% in Q1 2026, buying an estimated $197K and bringing the position to 19,667 shares worth $3.72M. The position accounts for 0.01% of the portfolio, ranked #855.

Federated Hermes first reported a position in JAZZ in Q3 2013 and has held it in 50 quarters since. The position peaked at $18.9M in Q4 2020. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Federated Hermes held 19,667 shares of Jazz Pharmaceuticals worth $3.72M as of Q1 2026.
  • Federated Hermes bought 1,126 Jazz Pharmaceuticals shares in Q1 2026, an estimated $197K.
  • Jazz Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q1 2026, its #855 holding.
  • Federated Hermes first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
  • Federated Hermes's Jazz Pharmaceuticals position peaked at $18.9M in Q4 2020.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.